Which contraceptive method is safest and most effective for a 32-year-old nulliparous woman with premature coronary artery disease, prior myocardial infarction, normal ejection fraction, paroxysmal atrial fibrillation, currently taking apixaban (Eliquis), carvedilol (Coreg), lisinopril, and rosuvastatin (Crestor), who has heavy menstrual bleeding and uses condoms for contraception?

Levonorgestrel IUD is the Safest and Most Effective Contraceptive Option

For this patient with premature CAD, prior MI, and paroxysmal AF on anticoagulation, a levonorgestrel intrauterine device (LNG-IUD) is the optimal choice—it provides highly effective contraception without increasing cardiovascular risk and will simultaneously treat her heavy menstrual bleeding.

Rationale for Recommendation

Why Combined Hormonal Contraceptives Are Contraindicated

This patient has established arterial cardiovascular disease (prior MI) and is only 32 years old, making combined oral contraceptives (COCs) absolutely contraindicated. The evidence is clear:

• COCs increase MI risk 2.0-2.7 fold in women with cardiovascular risk factors 1
• Women with prior MI using COCs face substantially elevated recurrent event risk 1
• The WHO case-control study demonstrated that even non-smoking women with hypertension (which she has, given her lisinopril use) have a 16.4-fold increased MI risk when using COCs 1
• This represents a WHO Category 4 condition (unacceptable health risk) for combined hormonal contraception 2

Why Progestin-Only Methods Are Safe

The French Society of Endocrinology guidelines provide reassuring data on progestin-only contraception:

• Levonorgestrel IUDs show no significant increase in venous thromboembolism risk (OR: no excess risk noted) 1
• Low-dose progestins do not affect hemostatic parameters 1
• Microdose progestin-based contraceptives and levonorgestrel IUDs have "very reassuring" epidemiological data with no significant VTE increase relative to non-users 1

Additional Benefits for This Patient

The LNG-IUD addresses multiple clinical needs simultaneously:

1. Treats heavy menstrual bleeding: This is a primary indication for LNG-IUD and will reduce her 10-day menstrual duration
2. Highly effective contraception: Failure rate <0.2% with perfect use 2
3. No drug interactions: Unlike oral contraceptives, the LNG-IUD has no interactions with her cardiac medications (Eliquis, Coreg, Lisinopril, Crestor) 3, 4
4. No increased bleeding risk: Despite her anticoagulation with apixaban, the LNG-IUD is safe—the local progestin effect actually reduces menstrual blood loss

Alternative Options (Less Optimal)

Progestin-Only Pills (POPs)

• Acceptable from cardiovascular standpoint (desogestrel 75 mcg, norethisterone 350 mcg show no excess VTE risk) 1
• However: Less effective than IUD (failure rate 0.3% vs 0.1-0.2%), requires daily compliance, and won't treat her heavy bleeding as effectively

Barrier Methods

• Condoms alone have 18% typical-use failure rate 2
• Unacceptable given that pregnancy would pose extreme cardiovascular risk in this patient with prior MI and AF

Depot Medroxyprogesterone Acetate (DMPA/Depo-Provera)

• Should be avoided: Studies show concerning trends toward increased VTE risk (OR: 2.19, with one study showing significant increase) 1
• High-dose progestin formulation may explain these results

Critical Pitfalls to Avoid

1. Never prescribe estrogen-containing contraception to women with established cardiovascular disease—this is an absolute contraindication
2. Don't rely on condoms alone in high-risk cardiac patients where pregnancy could be life-threatening
3. Avoid DMPA given the concerning thrombotic signals in the literature
4. Don't assume anticoagulation contraindicates IUD placement—the LNG-IUD actually reduces bleeding

Implementation

• Insert LNG-IUD (52 mg levonorgestrel system—Mirena, Liletta)
• Can be placed at any time in menstrual cycle if pregnancy excluded
• Counsel that irregular bleeding may occur for 3-6 months before amenorrhea develops
• Continue apixaban without interruption for IUD insertion (no need to hold anticoagulation)
• Expect significant improvement in heavy menstrual bleeding within 3-6 months

The LNG-IUD uniquely addresses this patient's contraceptive needs, cardiovascular safety profile, and menstrual concerns in a single intervention 1, 2, 5.